ESCLEROSIS MÚLTIPLE
![Foto de ESCLEROSIS MÚLTIPLE](/img/grupo.png)
![Foto de Dokuz Eylül University](/img/noimage_org.png)
Dokuz Eylül University
Esmirna, TurquíaPublications en collaboration avec des chercheurs de Dokuz Eylül University (7)
2023
-
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713
-
Comparative effectiveness in multiple sclerosis: A methodological comparison
Multiple Sclerosis Journal, Vol. 29, Núm. 3, pp. 326-332
-
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis
European Journal of Neurology, Vol. 30, Núm. 4, pp. 1014-1024
2022
-
Confirmed disability progression as a marker of permanent disability in multiple sclerosis
European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334
-
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
Neurology, Vol. 99, Núm. 17, pp. E1926-E1944
2021
-
Determinants of therapeutic lag in multiple sclerosis
Multiple Sclerosis Journal, Vol. 27, Núm. 12, pp. 1838-1851
-
Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
Neurology, Vol. 96, Núm. 24, pp. E2989-E3002